Codeine in Sickle Cell Disease

Phase 1

Completed

• Conditions: Sickle Cell Disease

• Registration Number: NCT00174538
• Lead Sponsor: PriCara, Unit of Ortho-McNeil, Inc.

Brief Summary

The objective of this study is to determine if a subject's genetic make-up would affect the treatment response to codeine in subjects with sickle cell disease.

Detailed Description

People with sickle cell disease require oral pain medications to manage an acute pain crisis. Sometimes these individuals fail to obtain adequate pain relief with the medications prescribed for outpatient use resulting in emergency room visits and hospital admissions. Subsequently, many patients are admitted to the hospital for pain management for a few days until the pain crisis resolves. The most common medications prescribed to sickle cell individuals for outpatient use include codeine and hydrocodone containing medications (i.e. Tylenol #3™, Vicodin™, Lortab™). These medications must be broken down in the body to make the active pain reliever (morphine or hydromorphone, respectively). Some individuals may not be able to break down these medications to the active pain reliever; therefore, these individuals will likely continue to experience pain unless they take other pain medications. We will determine whether genotype estimates the ability of CYP2D6 to break down codeine to the active pain reliever in individuals with sickle cell disease.

Study Timeline

• Study Start: 2005-03
• Status Verified: 2005-07
• Study First Submitted: 2005-09-09
• Study First Submitted QC: 2005-09-09
• Study First Posted: 2005-09-15
• Study Completion: 2005-12
• Last Update Submitted: 2011-06-29
• Last Update Posted: 2011-06-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Age >= 18 years old
• Sickle cell disease (HbSS)
• Hydrocodone- or codeine-containing medications to manage an acute pain crisis in the past

Exclusion Criteria

• Renal dysfunction, serum creatinine (SCr) > 2.0 mg/dl
• Hepatic dysfunction, AST, ALT or direct bilirubin > 3 x upper limit of normal (ULN)
• Codeine allergy
• Medications shown to induce or inhibit CYP2D6
• Women who are pregnant or breast feeding
• Unable to provide written, informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
CYP2D6 genotype
Plasma morphine and codeine concentrations

Secondary Outcome Measures

Name	Time	Method
Hospitalizations and admissions
Disease severity

Trial Locations

Locations (1)

University of Illinois Medical Center; 🇺🇸 Chicago, Illinois, United States